

Amendments to the Claims:

Following is a complete listing of the claims pending in the application, as amended:

1. (Currently Amended) A method for treating ~~up-regulating the blood interleukin-10 (IL-10) level in a human subject~~ multiple sclerosis in a human subject, comprising:

orally administering interferon-tau to the subject at a daily dosage of at least about 9×10^8 Units ~~greater than 5×10^8 Units to produce an initial measurable increase in the subject's blood IL-10 level, relative to the blood IL-10 level in the subject in the absence of interferon-tau administration, and~~

continuing to orally administer interferon-tau to the subject at said daily dose ~~on a regular basis of at least several times per week, independent of changes in the subject's blood IL-10 level, until a desired clinical endpoint is achieved.~~

2. (Original) The method of claim 1, wherein said administering comprises administering an interferon-tau selected from ovine interferon-tau and bovine interferon-tau.

3. (Original) The method of claim 2, wherein said administering comprises administering ovine interferon-tau having a sequence identified as SEQ ID NO:2 or SEQ ID NO:3.

4. (Currently amended) The method of claim 1, wherein said ~~oral administration is to~~ orally administering comprises orally administering a dosage form for release of interferon-tau to the intestinal tract of the subject.

Claims 5-15 (Cancelled)

16. (Original) The method of claim 1, further comprising administering a second therapeutic agent to the subject.

17. (Currently amended) The method of claim 16, wherein said second therapeutic agent is ~~selected from the group consisting of anti-viral agents, anti-cancer agents, and agents~~ an agent suitable for treatment of autoimmune disorders multiple sclerosis.

Claims 18-20 (Cancelled)